Centogene
189 articles about Centogene
-
CENTOGENE Announces Statewide COVID-19 Testing for Nursing Homes in Mecklenburg-Western Pomerania, Germany
5/12/2020
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced it will be offering COVID-19 testing for nursing homes in the state of Mecklenburg-Western Pomerania, Germany - the location of the Company’s headquarters.
-
Blueprint for Germany: CENTOGENE Provides Coronavirus Testing for German High School
5/8/2020
CENTOGENE, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced that it will be providing its fully validated SARS-CoV-2-PCR tests to students from the Carolinum High School, the largest high school in Neustrelitz, Germany.
-
CENTOGENE Expands Senior Leadership Team with Newly Appointed Senior Vice President Communication and Marketing
5/6/2020
CENTOGENE, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced the expansion of its Senior Leadership Team with the appointment of Angelos Baxevanis as Senior Vice President Communication and Marketing.
-
CENTOGENE Announces Global Expansion of COVID-19 Testing
5/5/2020
CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced it will expand its testing efforts for the novel coronavirus, or COVID-19. The Company was previously testing in Germany’s Mecklenburg-Western Pomerania region, and will now be offeri
-
Centogene Reports Financial Results For Full Year 2019 and Highlights Recent Progress
4/23/2020
Centogene N.V. announced a corporate update and reported its financial results for the year ended December 31, 2019.
-
CENTOGENE Releases a New Swab Product to Facilitate the Simple Diagnosis of COVID-19
4/21/2020
CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the production and global distribution of CentoSwab™.
-
CENTOGENE and Ubirch Create Secure Blockchain Solution for the Successful Fight Against COVID-19
4/17/2020
CENTOGENE and Ubirch announced a joint solution for the successful fight against the effects of SARS-CoV-2 ─ the virus causing COVID-19 ─ on the economy and social life in Germany.
-
CENTOGENE Announces Commencement of Testing for COVID-19
3/18/2020
CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that it will commence testing for the novel coronavirus, or COVID-19.
-
CENTOGENE Announces Departure of Dirk Ehlers From Executive Board
3/9/2020
CENTOGENE (Nasdaq: CNTG) ─ The Company today announced that Dr. Dirk H. Ehlers, COO and President of its Clinical Diagnostics Division, has decided to step down from his role after the Annual General Meeting in June 2020 and leave the Company for personal reasons
-
CENTOGENE Marks Rare Disease Day 2020 With a Global Line up of Events
2/29/2020
CENTOGENE will be raising awareness and building community for all those affected by rare genetic diseases with simultaneous events in Berlin, Germany, Lahore, Pakistan, and Mexico City, Mexico on Rare Disease Day 2020.
-
CENTOGENE Expands Senior Leadership Team with Newly Appointed Chief Data Officer
2/25/2020
CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced the appointment of Dr. Vaibhav Joshi to the newly created role of Chief Data Officer
-
CENTOGENE Biobank Receives Accreditation from College of American PathologistsState-of-the-art Biorepository in Rostock, Germany is the first CAP-accredited repository outside the U.S.
2/12/2020
CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that its biorepository in Rostock, Germany, which they believe holds the largest diversity of positive tested cases in the field of inherited rare diseases, has received accreditation from the College of American Pathologists (CAP).
-
CentoMD® Update Reveals Continued Growth of Rare Hereditary Disease Knowledge BaseSupporting Patients for Accelerated Diagnosis and Treatment Development
12/16/2019
In an update released today by CENTOGENE (Nasdaq: CNTG) to CentoMD® - the Company’s data repository of epidemiologic, phenotypic, and clinical data, - since September 2019 the number of analyzed cases has grown by 11% to more than 400,000, and the number of total variants has increased to 12.2 million from across 120 countries.
-
CENTOGENE Expands Executive Leadership Team with the appointment of Philip Lambert, PhD
12/6/2019
CENTOGENE announced the expansion of its executive leadership team with the appointment of Philip Lambert, PhD in Cambridge, MA as Chief Scientific Officer.
-
Centogene reporting its financial results for the three months and nine months ended September 30, 2019
12/5/2019
CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, announced today a corporate update and reported financial results for the third quarter and the nine months ended September 30, 2019.
-
CENTOGENE to Announce Third Quarter 2019 Financial Results on 5th December 2019
12/2/2019
CENTOGENE N.V. announced that it will report its third quarter 2019 results on Thursday, 5th December 2019, and will host a conference call on that day at 8 a.m. Eastern Time.
-
With the Thanksgiving holiday fast-approaching in the United States, some investors are giving their thanks to five different pharma companies that became available on the stock exchange this month with an initial public offering.
-
CENTOGENE Announces Temporary Leave of Absence of Holger Friedrich from the Supervisory Board
11/21/2019
Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies.
-
CENTOGENE Signs New Collaboration with PTC Therapeutics for Global Diagnostic Testing ProgramAromatic L-amino Acid Decarboxylase (AADC) Deficiency
11/18/2019
Centogene N.V. announced that it has signed an agreement with PTC Therapeutics, Inc. for a global diagnostic program for aromatic L-amino acid decarboxylase deficiency.
-
CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.
11/13/2019
CENTOGENE announced a new data access and collaboration agreement with Pfizer Inc.